STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Italian authorities have today initiated an investigation into some employees of Elekta’s Italian operations for suspected antitrust violations.
Elekta General Counsel, Jonas Bolander, said: “Elekta has very clear policies and procedures regarding code of conduct and fair competition. Elekta has zero tolerance toward any deviation of its code of conduct, of which fair competition is one important element.”
Elekta is fully cooperating with the Italian authorities.
In fiscal year 2014/15 Italy accounted for 3.5 percent of Elekta’s total net sales.
# # #
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 17:45 CET on November 12, 2015.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com